Instead, retrospective data of first-line chemoimmunotherapy demonstrated ORRs of 29–60% and mPFS of 5–8 months in HER2 MUT NSCLC patients, similar of those attained in non-oncogene-addicted NSCLC [108,111,112,113]. Here, ERBB2 is linked to non-small cell lung carcinoma.